Thus, in spite of being recognized as a bona fide promoter of anti-androgenic therapy-resistant prostate cancer, Myc remained as an elusive molecular target for developing strategies to overcome Enzalutamide-resistance. This evidence concerns the gene MYC and Familial prostate cancer.